Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML. Launay O, et al. Vaccine. 2009 Feb 18;27(8):1184-91. doi: 10.1016/j.vaccine.2008.12.021. Epub 2009 Jan 9. Vaccine. 2009. PMID: 19135496 Clinical Trial.
[Vaccination in patients with cirrhosis].
Loulergue P, Launay O; le groupe GEVACCIM (Groupe d'Etude sur la Vaccination des Sujets Immunodéprimés). Loulergue P, et al. Among authors: launay o. Presse Med. 2009 Jul-Aug;38(7-8):1134-40. doi: 10.1016/j.lpm.2008.11.015. Epub 2009 Jan 29. Presse Med. 2009. PMID: 19185447 Review. French.
Why actively promote vaccination in patients with cirrhosis?
Loulergue P, Pol S, Mallet V, Sogni P, Launay O; GEVACCIM Group. Loulergue P, et al. Among authors: launay o. J Clin Virol. 2009 Nov;46(3):206-9. doi: 10.1016/j.jcv.2009.05.006. Epub 2009 Jun 4. J Clin Virol. 2009. PMID: 19501019 Review.
Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses.
Marchand-Janssen C, Loulergue P, Mouthon L, Mahr A, Blanche P, Deforges L, Lebon P, Cohen P, Pagnoux C, Le Guern V, Bienvenu B, Aouba A, Guillevin L, Launay O. Marchand-Janssen C, et al. Among authors: launay o. Rheumatology (Oxford). 2011 Jun;50(6):1099-105. doi: 10.1093/rheumatology/keq422. Epub 2011 Jan 21. Rheumatology (Oxford). 2011. PMID: 21258052
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial.
Launay O, Desaint C, Durier C, Loulergue P, Duval X, Jacomet C, Pialoux G, Ghosn J, Raffi F, Rey D, Ajana F, Colin de Verdière N, Reynes J, Foubert V, Roman F, Devaster JM, Delfraissy JF, Aboulker JP; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d'Investigation Clinique en Vaccinologie REIVAC). Launay O, et al. J Infect Dis. 2011 Jul 1;204(1):124-34. doi: 10.1093/infdis/jir211. J Infect Dis. 2011. PMID: 21628666 Free PMC article. Clinical Trial.
[Measles and pregnancy].
Anselem O, Tsatsaris V, Lopez E, Krivine A, Le Ray C, Loulergue P, Floret D, Goffinet F, Launay O. Anselem O, et al. Among authors: launay o. Presse Med. 2011 Nov;40(11):1001-7. doi: 10.1016/j.lpm.2011.07.002. Epub 2011 Aug 31. Presse Med. 2011. PMID: 21885237 French.
Questions for biotechs: REIVAC.
Loulergue P, Duval X, Galtier F, Lenzi N, Laurichesse H, Launay O. Loulergue P, et al. Among authors: launay o. Hum Vaccin. 2011 Feb;7(2):142-3. doi: 10.4161/hv.7.2.15130. Hum Vaccin. 2011. PMID: 21937881 No abstract available.
487 results